News | November 25, 2021
ADB approves US $ 1.5 bn for Covid-19 vaccines in India
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
This is a shot in the arm for the vaccine manufacturers
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Subscribe To Our Newsletter & Stay Updated
